Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Abstract
Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. Within 90 minutes after receiving a single intravenous dose of the drug, all six volunteers had a systemic inflammatory response characterized by a rapid induction of proinflammatory cytokines and accompanied by headache, myalgias, nausea, diarrhea, erythema, vasodilatation, and hypotension. Within 12 to 16 hours after infusion, they became critically ill, with pulmonary infiltrates and lung injury, renal failure, and disseminated intravascular coagulation. Severe and unexpected depletion of lymphocytes and monocytes occurred within 24 hours after infusion. All six patients were transferred to the care of the authors at an intensive care unit at a public hospital, where they received intensive cardiopulmonary support (including dialysis), high-dose methylprednisolone, and an anti-interleukin-2 receptor antagonist antibody. Prolonged cardiovascular shock and acute respiratory distress syndrome developed in two patients, who required intensive organ support for 8 and 16 days. Despite evidence of the multiple cytokine-release syndrome, all six patients survived. Documentation of the clinical course occurring over the 30 days after infusion offers insight into the systemic inflammatory response syndrome in the absence of contaminating pathogens, endotoxin, or underlying disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although the solid phase assay does not replicate in vivo presentation of TGN1412, which is not fully understood, it does induce substantial cytokine release equivalent to that reported in trial volunteers.”
From Severity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release (2013) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“In 2006, a life-threatening 'cytokine storm', not predicted by pre-clinical safety testing, rapidly occurred in all six healthy volunteers during the phase I clinical trial of the CD28 superagonist monoclonal antibody (mAb) TGN1412.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“One of the most striking features of the TGN1412-mediated 'cytokine storm' observed in humans was substantial TNF-a release within the first hour of infusion followed by dramatic increases in IFN-g, IL-2, IL-6, IL-8 and IL-10 plasma concentrations within 4 h (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“Concentrations of TNF-a measured by ELISA in culture supernatants collected 24 h after in vitro TGN1412 stimulation were also consistent with the peak concentrations reported in trial volunteers, with the considerable caveat that a comparison is being made between an in vitro system and an in vivo response.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“However, despite similar in vitro expression kinetics for IFN-g following TGN1412 stimulation, the concentrations of IFN-g were far lower than TNF-a responses in vitro, and an order of magnitude lower than concentrations of IFN-g predicted from in vivo responses in trial participants (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“10.1073/pnas.0501997102”
Cited work 10.1073/pnas.0501997102 · retracted 2009-07-09 · notice 10.1073/pnas.0906977106 · this paper published 2006-09-07
Citations
Cites
1 retracted
Gon, Y., Wood, M. R., Kiosses, W. B., Jo, E., Sanna, M. G., Chun, J., & Rosen, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501997102 · Cited by 128
RetractedBone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Bernard, G. R., Artigas, A., Brigham, K. L., Carlet, J., Falke, K., Hudson, L., Lamy, M., Legall, J. R., Morris, A., & Spragg, R. (1994) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.149.3.7509706 · Cited by 6,746
Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans
Hotchkiss, R. S., Tinsley, K. W., Swanson, P. E., Schmieg, R. E., Hui, J. J., Chang, K. C., Osborne, D. F., Freeman, B. D., Cobb, J. P., Buchman, T. G., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6952 · Cited by 934
Clinical risks for development of the acute respiratory distress syndrome.
Hudson, L. D., Milberg, J. A., Anardi, D., & Maunder, R. J. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.2.7842182 · Cited by 890
Brivet, F. G., Kleinknecht, D. J., Loirat, P., & Landais, P. J. M. (1996) · Critical Care Medicine · doi:10.1097/00003246-199602000-00003 · Cited by 879
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203
Cited by
Items 1,901–2,000 of 2,162
Biomarkers of Tolerance in Renal Transplantation
Braza, F., Degauque, N., Soulillou, J., & Brouard, S. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-398523-1.00065-3
Passive immunotherapy by T cell–engaging bispecific antibodies
Baeuerle, P. A., & Rattel, B. (2011) · Informa Healthcare eBooks · doi:10.3109/9781841848303.018 · Cited by 1
Type 1 Diabetes: Past, Present, and Future Therapies
Singh, P., Kokil, G. R., Tupally, K. R., Poddar, K., Tan, A., Venkatesan, T., Parekh, H. S., & Pastorin, G. (2016) · SpringerBriefs in applied sciences and technology · doi:10.1007/978-981-10-0602-9_4
MacKenzie, C. R., & Paget, S. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-09138-1.00027-9 · Cited by 19
Novel Immunomodulatory Pathways in the Immunoglobulin Superfamily
Rennert, P. D. (2016) · Springer eBooks · doi:10.1007/978-3-319-29827-6_2
The immune environment in ovarian cancer
Wouters, M. C. A. (2016) · University of Groningen research database (University of Groningen / Centre for Information Technology)
Reversing T Cell Dysfunction for Tumor Immunotherapy
Kane, L., & Delgoffe, G. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-29827-6_5
Cells for Severe Acute Lung Injury Therapeutic Potential of Mesenchymal Stem
Liu, K. D., Calfee, C. S., Lee, W., Matthay, M. A., Thompson, B., Read, E. J., & David, H. (2010)
Kelly, K. L. (2016) · UA Campus Repository (The University of Arizona)
Rasiuk, A. S. (2015) · The Atrium (University of Guelph)
Generation and Characterization of Recombinantly Polysialylated Antibody
Chen, C. (2011) · Spiral (Imperial College London) · doi:10.25560/6970 · Cited by 1
Insurance and indemnity coverage for clinical trials of medicines in Kenya
Wahome, S. K. (2015)
Agyeman, A. A. (2016) · Pharmacy & Pharmacology International Journal · doi:10.15406/ppij.2016.04.00103
“Moreover, it would have been much appropriate if a hospital premise was selected for the trial site other than a privately leased unit by Parexal which was inadequately resourced for the diagnosis and treatment of affected volunteers [7].”
BackgroundInfluentialHoutenbos, I., Santegoets, S. J. A. M., Westers, T. M., Waisfisz, Q., Kipriyanov, S. M., Denkers, F., Scheper, R. J., de Gruijl, T. D., Ossenkoppele, G. J., & van de Loosdrecht, A. A. (2006) · Blood · doi:10.1182/blood.v108.11.3710.3710
The Role of the USA Food and Drug Administration in Clinical Research
Glasser, S. P., Ashton, C. M., & Wray, N. P. (2014) · Springer eBooks · doi:10.1007/978-3-319-05470-4_6 · Cited by 1
reactions Cytokine storm in a mouse model of IgG-mediated hemolytic transfusion
Jhang, J. S., Spitalnik, S. L., Hod, E. A., et al. (2013)
Sadozai, H. (2016) · TSpace (University of Toronto)
Immunogenicity and Immune-Related Adverse Drug Reactions
Mihalcik, L., Bussiere, J. L., Jawa, V., Lepherd, M., Mytych, D. T., Sharma, A. M., Sirivelu, M. P., & Everds, N. E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64257-5
Watson, M. J. (2016) · OpenCommons at University of Connecticut (University of Connecticut)
Maradana, M. R. (2016) · The University of Queensland · doi:10.14264/uql.2016.1080
Assessing Cell-Mediated Immune Functions
Piché, M.-S., Freebern, W. J., & Herbrand, U. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64234-4
Safety Considerations for Biologics
Dempster, M., Weir, L. R., & Fagg, R. (2017) · Methods and principles in medicinal chemistry · doi:10.1002/9783527699124.ch11
Desarrollo clínico de nuevos medicamentos. Seguridad de los ensayos clínicos en voluntarios sanos
Dal‐Ré, R. (2016) · Medicina Clínica · doi:10.1016/j.medcli.2016.03.018
Wagar, L. E. (2013) · TSpace (University of Toronto)
Immune Therapies in Phase 1 Trials
Postel-Vinay, S. C., & Soria, J. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_32
Immunomodulation with Adjuvants and Cytokines
Kim, D. W., & Diab, A. K. (2018) · Wiley eBooks · doi:10.1002/9781118684535.ch9
Kang, K., Chung, J., Yang, J., & Kim, H. (2017) · Korean Journal of Transplantation · doi:10.4285/jkstn.2017.31.4.157
“T 세포의 활성화는 항 anti-CD3/ anti-CD28 단일 클론 항체가 결합된 면역자기비드(immunomagnetic bead; Dynabeads Ⓡ CD3/CD28 Cell Therapy Systems [CTS] TM)를 사용하여 수행한다.”
InfluentialAdjunctive Therapies in Abdominal Sepsis
Ryan, T., & Coakley, J. D. (2017) · Hot topics in acute care surgery and trauma · doi:10.1007/978-3-319-59704-1_23
Precision Medicine in the Management of Drug Allergy
Khan, D. A. (2018) · Current Treatment Options in Allergy · doi:10.1007/s40521-018-0159-3
Les anticorps monoclonaux dans le traitement des maladies rhumatismales auto-immunes
Ciurea, A. (2008) · Forum Médical Suisse ‒ Swiss Medical Forum · doi:10.4414/fms.2008.06433
Biomimetic Delivery of Regulatory T Cell Inducing Factors to Suppress Cutaneous Inflammation
Balmert, S. C. (2018) · D-Scholarship@Pitt (University of Pittsburgh)
Wagner, F. (2018) · Queensland University of Technology · doi:10.5204/thesis.eprints.116423
Future Needs in Issue Resolution of Problems That Arise in Drug Development
Pugsley, M. K., Abernathy, M. M., Whitney, T. M., Authier, S., Renger, J. J., & Curtis, M. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812206-8.00015-7
Translational Biomarkers: Application in the Clinical Development of Combination Therapies
Sukumar, S., & Caculitan, N. G. (2018) · Springer eBooks · doi:10.1007/978-981-13-0496-5_12
Al Zamil, M. (2018) · Open Access Journal of Translational Medicine & Research · doi:10.15406/oajtmr.2018.02.00051
Carratalá, J. V., Cano‐Garrido, O., Sánchez, J. M., Membrado, C., Pérez, E., Conchillo‐Solé, O., Daura, X., Sánchez‐Chardi, A., Villaverde, A., Arı́s, A., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/510636
Thymus-Derived CD4+CD25+ FOXP3+ Regulatory T Cells in GVHD
Edinger, M., & Hoffmann, P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812630-1.00013-x
Fry, T. J., & Jacoby, E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812630-1.00008-6
Engraftment and tolerance induction in cellular therapy : focus on mesenchymal stromal cells
Ljung, K. (2018) · Figshare
Wang, H., Yang, Z., & Shi, R. (2019) · Wiley eBooks · doi:10.1002/9781119289234.ch4
Lukka, P. B., Wagh, S., & Meibohm, B. (2019) · Wiley eBooks · doi:10.1002/9781119289234.ch9
Disease Interception in Autoimmune Diseases: From a Conceptual Framework to Practical Implementation
Suri, A. (2019) · Wiley eBooks · doi:10.1002/9781119289234.ch1
Milbrandt, E. B., Ishizaka, A., & Angus, D. C. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200701-0123up
Getting specifi c: monoclonal antibodies in multiple sclerosis
Martinꝉ, R. (2008)
Launch of the Alliance for Human Relevant Science
Ram, R. (2017) · Alternatives to Laboratory Animals · doi:10.1177/026119291704500109
Kell, D. B. (2008) · arXiv (Cornell University) · doi:10.48550/arxiv.0808.1371
“[1378] Suntharalingam, G.”
Nouvelles biothérapies immunosuppressives dans les transplantations d’organes
Charpentier, B. (2008) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)32751-7 · Cited by 6
Origins and Evolution of Drug Regulation
Williams, K. L. (2019) · Springer eBooks · doi:10.1007/978-3-030-17148-3_2
Cancer immunotherapy: Adoptive cell therapies, cytokine-related toxicities, and the kidneys
Edeani, A. (2019) · Journal of Onco-Nephrology · doi:10.1177/2399369319863433
KLRG1 and its role in Rheumatoid Arthritis
Thompson, C. (2019) · ORCA Online Research @Cardiff (Cardiff University)
Monoclonal Antibodies for Immune System-Mediated Diseases
Brennan, F. R., Smith, E., & Dudal, S. (2019) · Springer eBooks · doi:10.1007/978-3-030-10811-3_21
Braam, M. J. S., & Kieffer, T. J. (2018) · Health Science Inquiry · doi:10.29173/hsi254
Biomolecules Versus Smaller Chemicals in Toxicology: ICH, EU, and US Recommendations
Ruthsatz, M., Chiavaroli, C., Cassar, M. A., & Voisin, E. (2020) · Springer eBooks · doi:10.1007/978-3-642-36206-4_57-2 · Cited by 1
Severe childhood asthma: a common international approach?
Cj, H., Woltmann, G., Wardlaw, A. J., Ma, B., & De, S. (2008)
Janssen, E., Shulman, A. I., & Sundel, R. P. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0271-2.00014-6
To co-enrol or not to co-enrol: that is the question
Presneill, J. (2017) · Critical Care and Resuscitation · doi:10.1016/s1441-2772(23)00779-2
The Prudential Value of Autonomy
Pugh, J. (2020) · Oxford University Press eBooks · doi:10.1093/oso/9780198858584.003.0010
The Practical Dimension of Autonomy
Pugh, J. (2020) · Oxford University Press eBooks · doi:10.1093/oso/9780198858584.003.0006 · Cited by 1
Rational Decision-Making Capacity in End of Life Decision-Making
Pugh, J. (2020) · Oxford University Press eBooks · doi:10.1093/oso/9780198858584.003.0009
Four Distinctions Concerning Rationality
Pugh, J. (2020) · Oxford University Press eBooks · doi:10.1093/oso/9780198858584.003.0002
S11-4 Ethical, regulatory issues to learn from the TGN1412 case
Kurihara, C. (2008) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.39.113s
Jha, S. S. (2020) · IP International Journal of Orthopaedic Rheumatology · doi:10.18231/j.ijor.2020.006
Promising Preclinical Results for Immunotherapy in Multiple Myeloma
Bustoros, M. W., & Ghobrial, I. M. (2020) · The Hematologist · doi:10.1182/hem.v17.3.10361
Luo, W., Ige, O. O., Beacon, T. H., Su, R., Huang, S., Davie, J., & Lakowski, T. M. (2020) · Genome · doi:10.1139/gen-2020-0130 · Cited by 2
“The glucocorticoids hydrocortisone and prednisolone have 325 been used with success to treat the CSS caused by the monoclonal antibody TGN1412 along with 326 other supportive measures like mechanical ventilation (Suntharalingam et al. 2006).”
BackgroundRose, K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-823888-2.00008-9
Kwok, R. S., Ahene, A. B., Brown, M., & Hunter, C. (2020) · Bioanalysis · doi:10.4155/bio-2020-0259
Paradigms in Cancer Drug Development: A Universe with Many Galaxies
Hierro, C., & Rodon, J. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-47682-3_2
Assignment of quantities to biological medicines: an old problem re-discovered
Ristow, D. F. B. (2015)
Jäger, S., & Schwab, M. G. (2021) · Springer eBooks · doi:10.1007/978-3-642-36206-4_43-2
Toxicology and Nonclinical Safety Assessment in Pharmaceutical Discovery and Development
Reynolds, V. L., Abernathy, M. M., Baracani, R., Bhalli, J. A., Morford, L. L., Steeves, M. A., & Wang, W. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc291
Mediation of Tumor Cell Death by Naked Antibodies
Little, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-72599-0_6
Yang, X., Toyofuku, W. M., & Scott, M. D. (2021) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-021-00634-5
Cancer immunotherapy targeting T cell costimulatory molecules
Pardee, A. D. (2010) · D-Scholarship@Pitt (University of Pittsburgh)
Development risk management plans
Mayall, S. J., & Banerjee, A. K. (2014) · Elsevier eBooks · doi:10.1533/9781908818270.4.325
The Common Good and the Egalitarian Research Imperative
London, A. J. (2021) · Oxford University Press eBooks · doi:10.1093/oso/9780197534830.003.0004
Fear of the Common Good and the Neglect of Justice
London, A. J. (2021) · Oxford University Press eBooks · doi:10.1093/oso/9780197534830.003.0002
Murgaski, A., Kiss, M., Damme, H. V., Kancheva, D., Vanmeerbeek, I., Keirsse, J., Hadadi, É., Brughmans, J., Arnouk, S. M., Hamouda, A. E. I., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.25.474021
“However, due to the potential to generate extreme adverse events, clinical application 423 of agonist therapies must be performed with caution [45].”
BackgroundAvoiding Justice: Research at the Auction Block
London, A. J. (2021) · Oxford University Press eBooks · doi:10.1093/oso/9780197534830.003.0008
The Integrative Approach to Assessing and Managing Risk
London, A. J. (2021) · Oxford University Press eBooks · doi:10.1093/oso/9780197534830.003.0006
The Anvil of Neglect and the Hammer of Exploitation: Fault Lines in Research Ethics
London, A. J. (2021) · Oxford University Press eBooks · doi:10.1093/oso/9780197534830.003.0003
Herzyk, D. J., & Bussiere, J. L. (2008) · Wiley eBooks · doi:10.1002/9780470386385.fmatter
Liu, H., Wu, W., Sun, G., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3981894
Philippart, F., Cavaillon, J., & Dinarello, C. A. (2008) · Wiley eBooks · doi:10.1002/9783527626151.ch8 · Cited by 1
Sharma, P., Subudhi, S. K., Peggs, K. S., Goswami, S., Gao, J., Quezada, S. A., & Allison, J. P. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm068
Pieters, R. H. H., Vos, J. G., van der Laan, J. W., et al. (2011) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0346-0136-8_31
Research and Innovative Treatment
British Medical Association (2012) · doi:10.1002/9781444355666.ch14
Goodman, A. M., Tanaka, T. N., & Kaufman, D. S. (2017) · Current cancer research · doi:10.1007/978-3-319-63757-0_5
Parker, G. A., & Papenfuss, T. L. (2017) · Molecular and integrative toxicology · doi:10.1007/978-3-319-47377-2_1
Nicolle, L. (2006) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2006/435962
Nouvelles stratégies immunosuppressives en transplantation
Kervella, D., & Blancho, G. (2022) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2022.02.004
Immunotoxicology of Biopharmaceutics☆
Haggerty, H. G., Price, K., & Shenton, J. M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.02008-0
Immunotherapy in cancer: A review
Kulkarni, P. D., Kadam, S. C., Nair, S. M., Jankar, Y. A., Sharma, D., Badadhe, S. G., & Ghante, M. R. (2022) · IP International Journal of Comprehensive and Advanced Pharmacology · doi:10.18231/j.ijcaap.2022.005 · Cited by 1
Autoimmunity regulation within the tumor microenvironment
Palacín-Aliana, I., Carrión-Navarro, J., Ayuso‐Sacido, Á., & Garcia‐Romero, N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85415-3.00002-7
Tuosto, L. (2018) · Springer eBooks · doi:10.1007/978-3-319-67199-4_101843
Fain, J. H., & Gad, S. C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386454-3.00976-3
Knowledge-Driven, Data-Assisted Integrative Pathway Analytics
Reddy, P. S., Murray, S., & Liu, W. (2011) · IGI Global eBooks · doi:10.4018/978-1-60960-491-2.ch010
McGeachy, M. J. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732850338.793546604
Metadata
- Authors
- Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N.
- Affiliations
- Hammersmith Hospital (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-09-07
- Volume
- 355
- Issue
- 10
- Pages
- 1018-1028
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141989396
- Cited by
- 2,164
- References
- 18
- Citations by year
- 2026: 57 · 2025: 73 · 2024: 95 · 2023: 79 · 2022: 79 · 2021: 120 · 2020: 141 · 2019: 94 · 2018: 102 · 2017: 97 · 2016: 117 · 2015: 122 · 2014: 118 · 2013: 120 · 2012: 114
- FWCI
- 80.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- cytokine release syndrome, TGN1412, anti-CD28 monoclonal antibody, systemic inflammatory response syndrome, inflammatory cytokines, acute respiratory distress syndrome, disseminated intravascular coagulation, renal failure, drug-induced immunotoxicity
- MeSH terms
- Adult, Antibodies, Monoclonal, C-Reactive Protein, Critical Care, Double-Blind Method, Hemodynamics, Humans, Hypotension, Infusions, Intravenous, Leukopenia, Male, Multiple Organ Failure, Thrombocytopenia, Cytokines, CD28 Antigens, Disease Progression, APACHE, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.